Literature DB >> 7579128

Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine.

L H Lassen1, L L Thomsen, J Olesen.   

Abstract

In primates, histamine activates cerebral endothelial H1-receptors leading to formation of nitric oxide (NO). Twenty migraine patients received pretreatment with placebo or the histamine-H1-receptor antagonist, mepyramine, in a randomized, double blind fashion, followed in both groups by i.v. histamine (0.5 microgram kg-1 min-1 for 20 min). Headache characteristics were subsequently observed for 12 h. In patients given placebo histamine caused immediate headache during the infusion followed by a delayed migraine attack fulfilling IHS criteria for migraine without aura. The temporal profile of induced headache was exactly the same as after glyceryl trinitrate. Mepyramine pretreatment abolished both immediate headache and delayed migraine attacks. Our results suggest that a migraine attack can be caused by NO formation in the endothelium of cerebral arteries.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579128     DOI: 10.1097/00001756-199507310-00003

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  21 in total

1.  Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.

Authors:  Henrik Winther Schytz; Helle Holst; Lars Arendt-Nielsen; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2010-05-09       Impact factor: 7.277

Review 2.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

3.  Possible role of histamine (H1- and H2-) receptors in the regulation of meningeal blood flow.

Authors:  Mária Dux; Nina Schwenger; Karl Messlinger
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia.

Authors:  R Kagan; V Kainz; R Burstein; R Noseda
Journal:  Neuroscience       Date:  2013-06-25       Impact factor: 3.590

Review 5.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 6.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 7.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

8.  Patients with migraine with aura have increased flow mediated dilation.

Authors:  Fabrizio Vernieri; Leo Moro; Claudia Altamura; Paola Palazzo; Raffaele Antonelli Incalzi; Paolo Maria Rossini; Claudio Pedone
Journal:  BMC Neurol       Date:  2010-03-10       Impact factor: 2.474

Review 9.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 10.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.